Monte Rosa Therapeutics (GLUE) Net Cash Flow (QoQ) (2020 - 2026)
Monte Rosa Therapeutics (GLUE) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 138.20% |
| Dec 31, 2025 | -156.48% |
| Sep 30, 2025 | 1,638.19% |
| Jun 30, 2025 | 93.80% |
| Mar 31, 2025 | -247.72% |
| Dec 31, 2024 | 488.16% |
| Sep 30, 2024 | 84.33% |
| Jun 30, 2024 | 132.42% |
| Mar 31, 2024 | -140.61% |
| Dec 31, 2023 | 474.77% |
| Sep 30, 2023 | 315.70% |
| Jun 30, 2023 | -82.04% |
| Mar 31, 2023 | 94.67% |
| Dec 31, 2022 | -762.66% |
| Sep 30, 2022 | 125.02% |
| Jun 30, 2022 | 83.32% |
| Mar 31, 2022 | -1,097.25% |
| Dec 31, 2021 | -273.99% |
| Sep 30, 2021 | -94.73% |
| Jun 30, 2021 | 49.28% |